Enovis CORP(ENOV)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-07-03.

Enovis CORP (ENOV) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ENOV at 39.5/100 on a 32-signal composite quality model, placing it at rank #2,147 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (9.3) and profitability (10.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 46.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Enovis CORP reports quarterly revenue of $582.8M, net income of $-1.2M, free cash flow of $31.1M. Top institutional holders of ENOV by reported 13-F value include BlackRock, AMERICAN CENTURY COMPANIES, Context Capital Management, based on the most recent SEC filings. ENOV trades on the NYSE exchange and files with the SEC under CIK 1420800. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENOV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Enovis CORP directly from SEC EDGAR.